Trajectory of brain-derived amyloid beta in Alzheimer’s disease:where is it coming from and where is it going?  

作　　者：Ni Liu Anaer Haziyihan Wei Zhao Yu Chen Hongbo Chao 

机构地区：[1]Zhengzhou University,Zhengzhou 450001,China [2]Wuhan National Laboratory for Optoelectronics,Huazhong University of Science and Technology,Wuhan 430074,China [3]Huazhong University of Science and Technology,Wuhan 430074,China

出　　处：《Translational Neurodegeneration》2024年第1期478-496,共19页转化神经变性病(英文)

基　　金：supported by grants from the Startup Fund of Zhengzhou University(32213157);the Key Scientific Research Projects of Colleges and Universities in Henan Province(K20A180031);the Postdoctoral Startup Fund Zhengzhou University(997002);the National Natural Science Foundation of China(52208131).

摘　　要：Alzheimer’s disease(AD)is a progressive neurological disorder that primarily impacts cognitive function.Currently there are no disease-modifying treatments to stop or slow its progression.Recent studies have found that several peripheral and systemic abnormalities are associated with AD,and our understanding of how these alterations contribute to AD is becoming more apparent.In this review,we focuse on amyloid-beta(Aβ),a major hallmark of AD,summarizing recent findings on the source of brain-derived Aβand discussing where and how the brain-derived Aβis cleared in vivo.Based on these findings,we propose future strategies for AD prevention and treatment,from a novel perspective on Aβmetabolism.

关 键 词：Alzheimer’s disease Amyloid-β Periphery system Immune clearance 

分 类 号：R74[医药卫生—神经病学与精神病学]